Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers

[1]  Hongyu Yuan,et al.  Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers , 2010, European Journal of Clinical Pharmacology.

[2]  S. Shi,et al.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.

[3]  M. Ingelman-Sundberg,et al.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. , 2008, British journal of clinical pharmacology.

[4]  H. Yamano,et al.  Plasma concentration of rabeprazole after 8‐week administration in gastroesophageal reflux disease patients and intragastric pH elevation , 2008, Journal of gastroenterology and hepatology.

[5]  Y. Naito,et al.  Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype , 2008, Digestive Diseases and Sciences.

[6]  G. Sachs,et al.  The Gastric H,K ATPase as a Drug Target: Past, Present, and Future , 2007, Journal of clinical gastroenterology.

[7]  T. Shimosegawa,et al.  Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism , 2006, Journal of gastroenterology and hepatology.

[8]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[9]  T. Habuchi,et al.  Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes , 2006, European Journal of Clinical Pharmacology.

[10]  C. Perdomo,et al.  Long‐term prevention of erosive or ulcerative gastro‐oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5‐year study in the United States , 2005, Alimentary pharmacology & therapeutics.

[11]  Yong-meiHU,et al.  Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects , 2005 .

[12]  M. Robinson,et al.  Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications , 2004, Alimentary pharmacology & therapeutics.

[13]  Yusong Chen,et al.  Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study , 2003, American Journal of Gastroenterology.

[14]  A. Blum,et al.  Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors , 2003, Alimentary pharmacology & therapeutics.

[15]  T. Koike,et al.  The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.

[16]  R. Fass,et al.  Gastroesophageal reflux disease: presentation and assessment of a common, challenging disorder. , 2003, Clinical cornerstone.

[17]  K. Baisley,et al.  Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects , 2002, Alimentary pharmacology & therapeutics.

[18]  W. Orr,et al.  Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial , 2002, American Journal of Gastroenterology.

[19]  R. Hegedus,et al.  Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis , 2002, Alimentary pharmacology & therapeutics.

[20]  K. Sugano.  Rabeprazole: quest for the best PPI , 2002, Journal of Gastroenterology.

[21]  G. Sachs.  Improving on PPI-based therapy of GORD. , 2001, European journal of gastroenterology & hepatology.

[22]  阪井 俊介.  CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects , 2001 .

[23]  G. Sachs,et al.  Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents* , 1997, The Journal of Biological Chemistry.

[24]  T. Ishizaki,et al.  Metabolic disposition of lansoprazole in relation to the S‐mephenytoin 4′‐hydroxylation phenotype status , 1997, Clinical pharmacology and therapeutics.